Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometr

Trial Details

NCT ID
NCT06468215
Phase
NA
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Endometrial Cancer Uterine Cancer
Interventions
  • Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Endometrioid adenocarcinoma G2, diagnosis by pathological.
  • The lesion is limited to the endometrium.
  • FIGO (2009) staging is IA.
  • Age less than 45.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Endometrial Cancer Uterine Cancer Trials on Trialify →